Pregnancy loss · ovarian stimulation protocols for women undergoing ART
It is very uncertain whether oestrogen changes pregnancy loss (Oestr + Ant vs Ant) compared with no pretreatment (very low certainty).
2 findings from 1 review
Multiple pregnancy rate · ovarian stimulation protocols for women undergoing ART
The review found no eligible studies for this question.
2 findings from 1 review
OHSS rate (Oestr + Ant vs Ant) · ovarian stimulation protocols for women undergoing ART
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
OHSS · ovarian stimulation protocols for women undergoing ART
It is very uncertain whether oestrogen changes OHSS rate (Oestr + Ant vs Ag) compared with no pretreatment (very low certainty).
1 finding from 1 review
Global symptoms of PMS over 3 menstrual cycles1 · women with PMS
1 finding from 1 review
Withdrawals due to adverse events · women with PMS
1 finding from 1 review
Specific adverse events · women with PMS
1 finding from 1 review
Incontinence not improved (generic inverse variance) (women's observations) ‐ Systemic administration (any incontinence) · patients with urinary incontinence in post‐menopausal women
Oestrogen may leads to higher incontinence not improved (generic inverse variance) (women's… compared with placebo or no treatment (low certainty).
1 finding from 1 review
Incontinence not improved (generic inverse variance) (women's observations) ‐ Local administration (any incontinence) · patients with urinary incontinence in post‐menopausal women
It is very uncertain whether oestrogen changes incontinence not improved (generic inverse variance) (women's… compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Incontinent episodes over 24 hours ‐ Systemic administration · patients with urinary incontinence in post‐menopausal women
1 finding from 1 review
Number of women with urgency ‐ Systemic administration · patients with urinary incontinence in post‐menopausal women
Oestrogen showed no clear difference in number of women with urgency ‐ Systemic administration compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Number of women with urgency ‐ Local administration · patients with urinary incontinence in post‐menopausal women
Oestrogen probably leads to lower number of women with urgency ‐ Local administration compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Number with adverse effects ‐ Systemic administration · patients with urinary incontinence in post‐menopausal women
Oestrogen may leads to higher number with adverse effects ‐ Systemic administration compared with placebo or no treatment (low certainty).
1 finding from 1 review
Number with adverse effects ‐ Local administration · patients with urinary incontinence in post‐menopausal women
Oestrogen showed no clear difference in number with adverse effects ‐ Local administration compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
OHSS · ovulation induction in polycystic ovarian syndrome
1 finding from 1 review
Clinical pregnancy rate · ovulation induction in polycystic ovarian syndrome
It is very uncertain whether antioestrogen changes clomiphene citrate plus tamoxifen versus clomiphene citrate ‐… compared with antioestrogen (very low certainty).
2 findings from 1 review
Live birth rate · ovulation induction in polycystic ovarian syndrome
Antioestrogen showed no clear difference in clomiphene citrate versus tamoxifen ‐ Live birth rate compared with antioestrogen (low certainty).
1 finding from 1 review
Miscarriage · ovulation induction in polycystic ovarian syndrome
Antioestrogen showed no clear difference in clomiphene citrate versus tamoxifen ‐ Miscarriage rate compared with antioestrogen (low certainty).
1 finding from 1 review
Multiple pregnancy · ovulation induction in polycystic ovarian syndrome
It is very uncertain whether antioestrogen changes clomiphene citrate versus tamoxifen ‐ Multiple pregnancy compared with antioestrogen (very low certainty).
1 finding from 1 review
Incontinent episodes over 24 hours ‐ oestrogen + progesterone vs placebo · patients with urinary incontinence in post‐menopausal women
1 finding from 1 review